Market Cap
US$1.8b
Last Updated
2020/09/25 06:12 UTC
Data Sources
Company Financials +
Executive Summary
Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. More Details
Rewards
Risk Analysis
Snowflake Analysis
Acceptable track record with mediocre balance sheet.
Similar Companies
Share Price & News
How has Fagron's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ARSU.F has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
13.6%
ARSU.F
-4.5%
US Healthcare
-3.3%
US Market
1 Year Return
39.6%
ARSU.F
17.2%
US Healthcare
10.9%
US Market
Return vs Industry: ARSU.F exceeded the US Healthcare industry which returned 17.2% over the past year.
Return vs Market: ARSU.F exceeded the US Market which returned 10.9% over the past year.
Shareholder returns
| ARSU.F | Industry | Market | |
|---|---|---|---|
| 7 Day | 13.6% | -4.5% | -3.3% |
| 30 Day | 13.6% | -7.2% | -5.7% |
| 90 Day | 13.6% | -1.0% | 8.2% |
| 1 Year | 39.6%39.6% | 18.8%17.2% | 13.4%10.9% |
| 3 Year | 66.4%66.4% | 20.9%15.6% | 34.9%25.9% |
| 5 Year | n/a | 48.9%38.3% | 84.6%63.8% |
Price Volatility Vs. Market
How volatile is Fagron's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Fagron undervalued compared to its fair value and its price relative to the market?
8.9%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ARSU.F ($24.76) is trading below our estimate of fair value ($27.19)
Significantly Below Fair Value: ARSU.F is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: ARSU.F is poor value based on its PE Ratio (25.5x) compared to the US Healthcare industry average (21.2x).
PE vs Market: ARSU.F is poor value based on its PE Ratio (25.5x) compared to the US market (17.4x).
Price to Earnings Growth Ratio
PEG Ratio: ARSU.F is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: ARSU.F is overvalued based on its PB Ratio (6.8x) compared to the US Healthcare industry average (2.6x).
Next Steps
Future Growth
How is Fagron forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
13.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARSU.F's forecast earnings growth (13.8% per year) is above the savings rate (2.2%).
Earnings vs Market: ARSU.F's earnings (13.8% per year) are forecast to grow slower than the US market (23% per year).
High Growth Earnings: ARSU.F's earnings are forecast to grow, but not significantly.
Revenue vs Market: ARSU.F's revenue (6.9% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: ARSU.F's revenue (6.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARSU.F's Return on Equity is forecast to be high in 3 years time (24.3%)
Next Steps
Past Performance
How has Fagron performed over the past 5 years?
51.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARSU.F has high quality earnings.
Growing Profit Margin: ARSU.F's current net profit margins (10.7%) are higher than last year (10.2%).
Past Earnings Growth Analysis
Earnings Trend: ARSU.F's earnings have grown significantly by 51.8% per year over the past 5 years.
Accelerating Growth: ARSU.F's earnings growth over the past year (17.9%) is below its 5-year average (51.8% per year).
Earnings vs Industry: ARSU.F earnings growth over the past year (17.9%) underperformed the Healthcare industry 31.1%.
Return on Equity
High ROE: Whilst ARSU.F's Return on Equity (26.14%) is high, this metric is skewed due to their high level of debt.
Next Steps
Financial Health
How is Fagron's financial position?
Financial Position Analysis
Short Term Liabilities: ARSU.F's short term assets (€275.0M) exceed its short term liabilities (€241.6M).
Long Term Liabilities: ARSU.F's short term assets (€275.0M) do not cover its long term liabilities (€338.0M).
Debt to Equity History and Analysis
Debt Level: ARSU.F's debt to equity ratio (163.6%) is considered high.
Reducing Debt: ARSU.F's debt to equity ratio has reduced from 325.7% to 163.6% over the past 5 years.
Debt Coverage: ARSU.F's debt is not well covered by operating cash flow (17.7%).
Interest Coverage: ARSU.F's interest payments on its debt are well covered by EBIT (8.3x coverage).
Balance Sheet
Next Steps
Dividend
What is Fagron current dividend yield, its reliability and sustainability?
0.70%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ARSU.F's dividend (0.71%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.75%).
High Dividend: ARSU.F's dividend (0.71%) is low compared to the top 25% of dividend payers in the US market (5.03%).
Stability and Growth of Payments
Stable Dividend: ARSU.F is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: ARSU.F is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: ARSU.F is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ARSU.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.7yrs
Average management tenure
CEO
Rafael Padilla (42 yo)
2.83yrs
Tenure
€768,000
Compensation
Mr. Rafael Padilla has been Chief Executive Officer at Fagron NV since November 27, 2017 and served as its Area General Manager of South America and Southern Europe since October 25, 2016. Mr. Padilla serv ...
CEO Compensation Analysis
Compensation vs Market: Rafael's total compensation ($USD894.58K) is below average for companies of similar size in the US market ($USD4.65M).
Compensation vs Earnings: Rafael's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.83yrs | €768.00k | no data | |
| CFO & Executive Director | 3.92yrs | no data | no data | |
| Global Legal Affairs Director | 2.67yrs | no data | no data | |
| Chief Communications Officer | no data | no data | no data | |
| Global Marketing Communications Director | 0.25yr | no data | no data | |
| Global HR Director | 2.67yrs | no data | no data | |
| President of North America | 0.67yr | no data | no data | |
| President of North America | no data | no data | no data |
2.7yrs
Average Tenure
42yo
Average Age
Experienced Management: ARSU.F's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.83yrs | €768.00k | no data | |
| CFO & Executive Director | 3.92yrs | no data | no data | |
| Non-Executive Director | 3.92yrs | €30.00k | no data | |
| Independent Director | 3.33yrs | €31.20k | no data | |
| Non-Executive Director | 0.92yr | €38.40k | no data | |
| Independent Director | 0.75yr | no data | no data | |
| Independent Director | 4.08yrs | €38.40k | no data | |
| Independent Chairman | 3.33yrs | €100.00k | no data |
3.3yrs
Average Tenure
47yo
Average Age
Experienced Board: ARSU.F's board of directors are considered experienced (3.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Fagron NV's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Fagron NV
- Ticker: ARSU.F
- Exchange: OTCPK
- Founded: 1990
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: €1.532b
- Listing Market Cap: €1.785b
- Shares outstanding: 72.08m
- Website: https://www.fagron.com
Number of Employees
Location
- Fagron NV
- Venecoweg 20A
- Nazareth
- East Flanders
- 9810
- Belgium
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 4A5 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Oct 2007 |
| FAGR | ENXTBR (Euronext Brussels) | Yes | Ordinary Shares | BE | EUR | Oct 2007 |
| 0HNZ | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Oct 2007 |
| FAGRB | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Oct 2007 |
| ARSU.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Oct 2007 |
Biography
Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. It prepares personalized ready-to-use medication in its sterile a ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/25 06:12 |
| End of Day Share Price | 2020/09/24 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.